ClinicalTrials.gg
RecruitingNCT04095468Updated Sep 19, 2019

Organ-preserving Management in Patients With Complete or Near-complete Tumour Response After Preoperative Radio(Chemo)Therapy for Rectal Cancer

An observational study in Rectal Neoplasms and Rectal Cancer, sponsored by Maria Sklodowska-Curie National Research Institute of Oncology. Recruiting at 7 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-19.

Sponsored by Maria Sklodowska-Curie National Research Institute of Oncology · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2021, 5 years 10 months ago, but the record still lists the study as recruiting.
  • Started Sep 2017; still recruiting 9 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
215
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Rectal Neoplasms with a site in Poland — 4 open to participants now, 8 under way, 3 of them phase 3. Rectal Neoplasms · Poland.

Started
2017
with 1 other
Observational
3 of 31
2 open now
Registered
19th of 31
by date
Lead sponsor
6 of 31
Maria Sklodowska-Curie National Research Institute of Oncology

Among the 31 studies in Rectal Neoplasms with a site in Poland, this one is one of 2 that started in 2017, is one of 3 observational ones, and was the 19th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

4 of the 31 studies in Rectal Neoplasms with a site in Poland are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Rectal Neoplasms with a site in Poland, or all of them as a file.
02

Study summary

Watch-and-wait strategy in rectal cancer is gaining momentum. There is a large variability in reporting the proportion of patients achieving clinical complete response (cCR) after routinely delivered preoperative radio(chemo)therapy, likely because of patients' selection. This proportion in population-based level is poorly defined. In addition, predictive factors for cCR are also poorly defined. It is known that cCR response is observed often in small tumours. However, cCR proportion in large cancers has not been sufficiently evaluated. For example, even though pathological complete response (pCR) does occur in large fixed cancer, it is unknown whether cCR does also occur because persistent fibrous stroma may mimic residual cancer in all of such cases.

This is a prospective observational population-based cohort study on low rectal cancer to answer the question of how often clinical or near-clinical tumour response occur after routinely delivered preoperative radiotherapy in relation to the pre-treatment tumour characteristics. The additional question was how often pCR occur in relation to the pre-treatment tumour characteristics in the patients managed by total mesorectal excision because of persistent tumour after radiotherapy. The additional aim was the implementation of watch-and-wait strategy or full-thickness local excision (as an option instead of total mesorectal excision in the patients with sustained near-cCR) within a frame of a prospective study. In the patients managed by organ preservation, the secondary outcome measures were: i) local regrowth rate, ii) effectiveness of salvage surgery, iii) disease-free survival at 3 years and overall survival at 5 years, iv) anorectal function.

03

Conditions studied

  • Rectal Neoplasms
  • Rectal Cancer

Browse trials for

Keywords

  • rectal cancer
  • preoperative radiotherapy
  • organ preservation
  • watch-and-wait
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

140 patients with "resectable" cancer and 75 patients with threatened mesorectal fascia as assessed on multidisciplinary tumor board.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary rectal cancer
  • Low tumour (accessible by digital rectal examination)
  • Routine preoperative radio(chemo)therapy according to the institutional policy; short-course radiation and immediate surgery is not allowed.
  • for watch-and-wait strategy or local excision in patients with cCR and near-cCR

Exclusion criteria

Exclusion Criteria:

  • Recurrent cancer
  • Cancers situated in the upper rectum
  • Distant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
215 participants (estimated)
Patient registry
No

Groups and cohorts

  • Resectable rectal cancer

    Radiation: Preoperative Radio(Chemo)Therapy

  • Rectal cancer with threatened mesorectal fascia

    Radiation: Preoperative Radio(Chemo)Therapy

Interventions

  • RadiationPreoperative Radio(Chemo)Therapy

    Preoperative radiotherapy +/- chemotherapy, then surgery (total mesorectal excision) or watch-and-wait

06

What researchers measure

Primary outcomes

  1. Percentages of cCR and near-cCR in the patients with "resectable" cancer

    Time frame: 11 weeks from the start of radiotherapy

  2. Percentages of cCR and near-cCR in the patients with threatened mesorectal fascia.

    Time frame: 11 weeks from the start of radiotherapy

  3. Percentages of cCR and near-cCR in relation to the selected tumour characteristics.

    The selected tumour characteristics: TN categories, tumour length, degree of circumferential involvement, tumour mobility on digital rectal examination (mobile, tethered, fixed) and status of mesorectal fascia (threatened or not).

    Time frame: 11 weeks from the start of radiotherapy

  4. Percentages of pCR in the patients after total mesorectal excision performed because of tumour persistence.

    Time frame: 12 weeks from the start of radiotherapy

Secondary outcomes

  1. Local regrowth rate

    Time frame: 5 years

  2. Disease-free survival

    Time frame: 3 years

  3. Overall survival

    Time frame: 5 years

  4. Anorectal function assessed by low anterior resection syndrome (LARS) score

    The questionnaire will be completed by patients. It includes 5 items related to anorectal function. The range of the score (0-42) is divided into 0 to 20 (no LARS), 21 to 29 (minor LARS) and 30 to 42 (major LARS).

    Time frame: 3 years

07

Study locations

6 of 7 sites recruiting
  • Maria Skłodowska-Curie Institute - Oncology Center
    Warsaw, Mazovian 02-781, Poland
    Recruiting
    • Krzysztof Bujko, M.D. PhD · ContactKrzysztof.Bujko@coi.pl · +48601207466
    • Krzysztof Bujko, M.D. PhD · Principal investigator
  • Collegium Medicum Nicolaus Copernicus University and Oncology Centre
    Bydgoszcz, Poland
    Recruiting
    • Michał Jankowski, M.D. · Contact
    • Michał Jankowski, M.D. · Principal investigator
  • Regional Oncological Centre
    Kielce, Poland
    Recruiting
    • Jacek Sadowski, M.D. · Contact
    • Jacek Sadowski, M.D. · Principal investigator
  • Jagiellonian Medical University College
    Kraków, Poland
    Not yet recruiting
    • Piotr Richter, M.D. · Contact
    • Piotr Richter, M.D. · Principal investigator
  • St. John's Cancer Center
    Lublin, Poland
    Recruiting
    • Małgorzata Jankiewicz, M.D. · Contact
    • Małgorzata Jankiewicz, M.D. · Principal investigator
  • Silesian Oncological Centre
    Wrocław, Poland
    Recruiting
    • Jolanta Szelachowska, M.D. · Contact
    • Jolanta Szelachowska, M.D. · Principal investigator
  • NU-MED Centre for Cancer Diagnosis and Treatment
    Zamość, Poland
    Recruiting
    • Marek Mazurek, M.D. · Contact
    • Marek Mazurek, M.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2017 (actual). Primary completion is estimated for Jan 2021, 39 months after the start.

Of 214 non-industry observational studies under Rectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 118. This study's planned 39 months is below that.

Counting every sponsor, half of 229 studies reached it within 45 months; a quarter within 24 and three quarters within 116.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2019
First posted
Sep 19, 2019
StartActual
Sep 18, 2017
Primary completionEst.
Jan 1, 2021
CompletionEst.
Jan 1, 2026
Last update
Sep 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04095468
Lead sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Collaborators
Polish Society of Surgical Oncology
Responsible party
Sponsor
First posted
Sep 19, 2019
Start date
Sep 18, 2017
Primary completion
Jan 1, 2021 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Sep 19, 2019

Study contacts

Krzysztof Bujko, M.D. PhD
Contact
Krzysztof.Bujko@coi.pl
+48601207466

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion